A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
|Videos|September 17, 2020
The Harms of Vaccine Hesitancy
Author(s)Kevin Kunzmann
What we've seen non-immunized communities do for previously eradicated outbreaks.
Advertisement
A new study published in The Lancet last week showed
The findings from the 284,000-adult assessment painted a concerning image of global vaccine hesitancies at a time when coronavirus 2019 (COVID-19) vaccine candidates are nearing regulatory consideration. But such an issue is not coronavirus-centric.
Just last year, the World Health Organization (WHO) declared vaccine hesitancy a top 10 global health threat.
In an interview with Contagion®, Dan Salmon, PhD, a commentator on the Lancet findings and a clinician with the Department of International Health at Johns Hopkins Bloomberg School of Public Health, discussed how vaccine hesitancy can be specific to not only the prophylaxis itself, but the disease, patient region, and time of consideration.
“It’s really in this climate that we see COVID, and we see the potential introduction of a COVID vaccine coming down the road,” he said. “And it’s exceedingly challenging because we already had huge challenges in vaccine hesitancy.”
Advertisement
Related to this article
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Advertisement
Advertisement